Navigation Links
Additional 8 Products of DK Sinopharma, Inc. are Included in 2010 Provincial Medical Insurance Catalogs in 4 Separate Provinces in the People's Republic of China
Date:2/22/2011

XI'AN, China, Feb. 22, 2011 /PRNewswire-Asia-FirstCall/ -- DK Sinopharma, Inc. (OTC Bulletin Board: DKSP) ("DK Sinopharma" or the "Company"), announced today that eight (8) of its products have been included in the 2010 Provincial Medical Insurance Catalogs in four (4) separate provinces in the People's Republic of China (the "PRC"). These products include: (i) our Huanglong Cough Granules, our Ganhai Stomach Recovery Capsule and our Heart Disease Relieving Capsule in the Provincial Medical Insurance Catalog for the Shaanxi Province (ii) our Ganhai Stomach Recovery Capsule and our Heart Disease Relieving Capsule in the Provincial Medical Insurance Catalogs for the Jiangxi Province (iii) our Ganhai Stomach Recovery Capsule and our Heart Disease Relieving Capsule in the Provincial Medical Insurance Catalog for Inner Mongolia Autonomous Region and (iv) our Heart Disease Relieving Capsule in the Provincial Medical Insurance Catalog for the Liaoning Province. These products are in additional to the previous thirteen (13) products which have previously been included in the National Medical Insurance Catalog.

"We are very proud of this great achievement, which we believe shows that the quality and curative effect of the Company's products are widely recognized by the government as well as by the doctors and patients," said Professor Dongke Zhao, the founder and CEO of DK Sinopharma. "In addition to the previous 13 products listed on the National Medical Insurance Catalog, the newly-listed products in the Provincial catalogs help to establish the brand identity of each of our products. Meanwhile, being included in the National and Provincial Medical Insurance Catalogs will enable patients to be reimbursed by government insurance for the use of our products. This achievement has been a great opportunity to demonstrate the competitive edge of the Company."

All of those newly-l
'/>"/>

SOURCE DK Sinopharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Pacira Pharmaceuticals Highlights Additional Safety Data on EXPAREL™ for Postsurgical Pain Relief at 2011 American Academy of Orthopaedic Surgeons Annual Meeting
2. Varian Medical Systems Board of Directors Authorizes Repurchase of Additional 12 Million Shares of Stock Through Fiscal Year 2012; Additional Accelerated Share Repurchase Program
3. MedQuist Holdings Inc. Announces Closing of Its Initial U.S. Public Offering and Acquisition of Additional Shares of MedQuist Inc.
4. Correction: New Mexico Software Unveils Additional Software Significantly Expanding Availability of Its Telemedicine Services
5. New Mexico Software Unveils Additional Software Significantly Expanding Availability of Its Telemedicine Services
6. HeartWare Receives Third Patient Allotment From FDA - Authorizing 94 Additional Patients - Under Continued Access Protocol for Pivotal U.S. Bridge-to-Transplant Clinical Trial
7. Optimer Pharmaceuticals Obtains Additional Fidaxomicin Patent
8. MiMedx Receives Additional CE Certification for Its HydroFix™ Technology
9. Stryker Announces Additional $500 Million Share Repurchase Program and Declares a 20% Increase in Quarterly Dividend
10. Neurologix Completes Additional $7 Million Financing
11. Additional Regional Medicare Carrier Initiates Coverage for Posterior Tibial Nerve Stimulation (PTNS) Delivered via Uroplastys Urgent® PC Neuromodulation System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... Aug. 28, 2015  CytomX Therapeutics, Inc., a biopharmaceutical ... today announced the filing of a registration statement on ... (SEC) relating to a proposed initial public offering of ... offered and the price range for the offering have ... common stock under the symbol "CTMX" on the NASDAQ ...
(Date:8/28/2015)... Aug. 28, 2015 Research ... of the "Investigation Report on China,s Bevacizumab Market ... by Roche under the trade name of Avastin, bevacizumab ... In Feb.26, 2010, it was approved by CFDA to ... China all come from Roche ...
(Date:8/28/2015)... 2015  Today, in final recognition of the Centers ... Week, 1-800 Contacts is sharing how to keep lens ... wearers who do not properly care for their lens ... Most contact lens wearers understand the ... lens case is sometimes overlooked.  When proper steps to ...
Breaking Medicine Technology:CytomX Files Registration Statement for Proposed Initial Public Offering 2Investigation Report on China's Bevacizumab Market 2015-2019 21-800 Contacts Shares Tips on How to Clean Lens Cases 2
... SPRINT-1 study presented at AASLD annual meeting, ... patients and those,who failed prior treatment, SAN ... ) today reported that a planned interim analysis ... investigational oral hepatitis C,protease inhibitor, in combination with ...
... COPENHAGEN, Denmark, October 31 , - DoctorConsult ... That Improve Clinician Decision Making and Health Care ... workflow and more than a,century of experience as ... to provide interactive clinical reference and clinical decision,support ...
Cached Medicine Technology:Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients 2Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients 3Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients 4Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients 5Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients 6Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients 7Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients 8Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients 9Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients 10Elsevier is Expanding eClinical Solutions in Europe 2Elsevier is Expanding eClinical Solutions in Europe 3
(Date:8/28/2015)... ... ... For Dallas, the time is nearing for the annual Heart Walk, and North ... American Heart Association hosts their well-known Heart Walk to raise money in awareness and ... be made. Walkers can participate in the cause and someone can also donate, even ...
(Date:8/28/2015)... ... 28, 2015 , ... As reported by Medical Daily on August 22 ... results that last for two years, the longest of any cellulite reduction system currently ... for a long-lasting, effective solution for their cellulite, according to Dr. Robert Weiss, director ...
(Date:8/28/2015)... Manistee, Michigan (PRWEB) , ... August 28, 2015 , ... ... in Western Michigan, joined as sponsor of the “Music With A Mission” benefit concert ... purpose behind the event was to raise money to support music education programs in ...
(Date:8/28/2015)... ... , ... Saint Petersburg, FL —Pocket Protein™, a protein beverage ... gluten, lactose or caffeine in a convenient 2 oz. pouch that never needs ... Awards. , Five consumer packaged goods (CPG) products were selected by the SupplySide ...
(Date:8/28/2015)... ... , ... Altima Technologies, Inc., the maker of popular NetZoom™ ... and audio-video devices, recently released Visio Stencils for the following product lines: ... VNX Series , Super Micro Computer SuperStorage, Hitachi Data Systems Virtual Storage Series, ...
Breaking Medicine News(10 mins):Health News:North Central Surgical Center’s Subsidiary Participates in Walk 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 3Health News:New Video Released on "Music With A Mission" Benefit Concert Headlining Artist Cadillac Three & Best Drug Rehabilitation 2Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 2Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 3Health News:Altima Updates NetZoom™ Visio® Stencil Library for Cisco, HP, and EMC Devices 2Health News:Altima Updates NetZoom™ Visio® Stencil Library for Cisco, HP, and EMC Devices 3
... cell research, experts say , , MONDAY, Nov. 3 (HealthDay ... mice from mouse bodies that had been frozen for ... raise the specter of resurrecting lost species a la ... said recreating woolly mammoths was "probably impossible." , ...
... study conducted by researchers at Georgia State University is ... of preemptive morphine prior to a painful procedure in ... adult rodents. These studies have serious implications for ... prior to surgery. Infant rodents that did not receive ...
... efforts to educate the public about HIV, a new ... University and Children,s Hospital Boston has found that two-thirds ... spreading HIV in the home. , The qualitative study ... minor children, in families with an HIV-infected parent about ...
... at the University of California, San Diego (UCSD) are ... revving up the immune system to combat a particularly ... is being offered to patients with chronic lymphocytic leukemia ... to initial treatment or harbors a particular chromosomal abnormality ...
... which claimed that homeopathy is just a placebo, published in ... George Lewith, Professor of Health Research at Southampton University comments: ... nor of the various vital assumptions made about the data. ... homeopathy works for some conditions but not others, or change ...
... increases 32% to $16.0 million. - Heart valve therapy products revenue rises 39.1% ... surgical ablation products revenue grows 21.7%. - Third quarter gross profit ... 2008 revenue guidance to $65 - $66 ... million., MINNEAPOLIS, Nov. ...
Cached Medicine News:Health News:Scientists Make Clones of Mice Dead 16 Years 2Health News:GSU study first to confirm long-term benefits of morphine treatment in infants 2Health News:Study finds fears of HIV transmission in families with infected parent 2Health News:Moores UCSD Cancer Center studying novel leukemia vaccine for high-risk patients 2Health News:New evidence for homeopathy 2Health News:ATS Medical Announces Third Quarter Results 2Health News:ATS Medical Announces Third Quarter Results 3Health News:ATS Medical Announces Third Quarter Results 4Health News:ATS Medical Announces Third Quarter Results 5Health News:ATS Medical Announces Third Quarter Results 6Health News:ATS Medical Announces Third Quarter Results 7Health News:ATS Medical Announces Third Quarter Results 8
Thermometer for Round Water Bath...
... The F340 is a basic laboratory system ... pH results can be obtained when used ... 3-in-1 electrode. • Fast and easy one ... recognition for five buffers (pH 1.68, 4.00, ...
... - the multifunctional high-end microplate reader with ... detection modes., Fluorescence Intensity - FRET ... - HTRF, AlphaScreen , Luminescence ... dual emission microplate reader with fastest read ...
GENios Pro, TECANs advanced, multi-functional injector reader offers simultaneous reagent dispensing and detection for monitoring of fast kinetic reactions...
Medicine Products: